TY - JOUR
T1 - Extracellular vesicle-based nucleic acid delivery
T2 - Current advances and future perspectives in cancer therapeutic strategies
AU - Massaro, Crescenzo
AU - Sgueglia, Giulia
AU - Frattolillo, Victoria
AU - Baglio, S. Rubina
AU - Altucci, Lucia
AU - Dell’aversana, Carmela
N1 - Funding Information:
This research was funded by AIRC-17217; VALERE: Vanvitelli per la Ricerca; Campania Regional Government Technology Platform Lotta alle Patologie Oncologiche: iCURE-B21C17000030007; Campania Regional Government FASE2: IDEAL; MIUR, Proof of Concept-EPICUREPOC01_00043-B64I19000290008; P.O.R. CAMPANIA FSE 2014/2020 ASSE III-B27D18001070006. Acknowledgments: Special thanks to Catherine Fisher for language editing.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/10
Y1 - 2020/10
N2 - Extracellular vesicles (EVs) are sophisticated and sensitive messengers released by cells to communicate with and influence distant and neighboring cells via selective transfer of bioactive content, including protein lipids and nucleic acids. EVs have therefore attracted broad interest as new and refined potential therapeutic systems in many diseases, including cancer, due to their low immunogenicity, non-toxicity, and elevated bioavailability. They might serve as safe and effective vehicles for the transport of therapeutic molecules to specific tissues and cells. In this review, we focus on EVs as a vehicle for gene therapy in cancer. We describe recent developments in EV engineering to achieve efficient intracellular delivery of cancer therapeutics and avoid off-target effects, to provide an overview of the potential applications of EV-mediated gene therapy and the most promising biomedical advances.
AB - Extracellular vesicles (EVs) are sophisticated and sensitive messengers released by cells to communicate with and influence distant and neighboring cells via selective transfer of bioactive content, including protein lipids and nucleic acids. EVs have therefore attracted broad interest as new and refined potential therapeutic systems in many diseases, including cancer, due to their low immunogenicity, non-toxicity, and elevated bioavailability. They might serve as safe and effective vehicles for the transport of therapeutic molecules to specific tissues and cells. In this review, we focus on EVs as a vehicle for gene therapy in cancer. We describe recent developments in EV engineering to achieve efficient intracellular delivery of cancer therapeutics and avoid off-target effects, to provide an overview of the potential applications of EV-mediated gene therapy and the most promising biomedical advances.
KW - Cancer
KW - Extracellular vesicles
KW - Gene therapy
KW - Nucleic acid delivery
UR - http://www.scopus.com/inward/record.url?scp=85092568777&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics12100980
DO - 10.3390/pharmaceutics12100980
M3 - Review article
AN - SCOPUS:85092568777
SN - 1999-4923
VL - 12
SP - 1
EP - 19
JO - Pharmaceutics
JF - Pharmaceutics
IS - 10
M1 - 980
ER -